Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
7
×
biotech
boston blog main
boston top stories
7
×
boulder/denver blog main
boulder/denver top stories
cancer
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
7
×
texas blog main
texas top stories
wisconsin blog main
7
×
wisconsin top stories
eli lilly
biogen
abbvie
cancer immunotherapy
clinical trials
deals
europe blog main
europe top stories
fda
merck
What
bio
roundup
drug
companies
week
alzheimer’s
buy
debut
moves
new
price
prices
acquisitions
activity
alliance
annual
approval
approvals
assessed
attention
biggest
biogen
biogen’s
biopharmaceutical
biotech
black
bristol
build
calls
ceo
changing
clamped
color
communities
company’s
conference
continue
convo
covid
crispr
Language
unset
Current search:
cancer
×
startups
×
" alzheimer's disease "
×
" wisconsin blog main "
×
" boston top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More